SEC Filings

Form 10-Q
BEIGENE, LTD. filed this Form 10-Q on 05/09/2018
Document Outline
Entire Document (5224.8 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - BeiGene, Ltd.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - BEIGENE, LTD.
Page 5 - BEIGENE, LTD.
Page 6 - BEIGENE, LTD.
Page 7 - BEIGENE, LTD.
Page 8 - Use of estimates
Page 9 - Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory
Page 10 - Business Combinations: Clarifying the Definition of a Business.
Page 11 - New accounting standards which have not yet been adopted
Page 12 - Level 2
Page 13 - 4. Business Combination
Page 14 - 5. Restricted Cash and Short-term Investments
Page 15 - 7. Property and Equipment
Page 16 - 9. Land Use Right
Page 17 - 12. Supplemental Balance Sheet Information
Page 18 - 13. Long-term Bank Loan
Page 19 - Accounting for the Shareholder Loan
Page 20 - 16. Net Loss Per Share
Page 21 - 18. Accumulated Other Comprehensive Income/(Loss)
Page 22 - 20. Shareholders Equity
Page 23 - Capital commitments
Page 24 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 25 - Recent Developments
Page 26 - Expenses
Page 27 - N/A
Page 28 - Selling, General and Administrative Expenses
Page 29 - Results of Operations
Page 30 - Cost of Sales
Page 31 - Selling, General and Administrative Expense
Page 32 - Use of Funds
Page 33 - Financing Activities
Page 34 - Contractual Obligations and Commitments
Page 35 - Debt Obligations
Page 36 - Recent Accounting Pronouncements
Page 37 - JOBS Act
Page 38 - Currency Convertibility Risk
Page 39 - Changes in Internal Control over Financial Reporting
Page 40 - If we encounter difficulties enrolling patients in our clinical trials, our clinical development act
Page 41 - If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfactio
Page 42 - Risks Related to Extensive Government Regulation
Page 43 - We believe that our drug candidates designation in China as Category 1 products should confer certai
Page 44 - Chinese manufacturing facilities have historically experienced issues operating in line with establi
Page 45 - Our drugs and any future approved drug candidates will be subject to ongoing regulatory obligations
Page 46 - If safety, efficacy, or other issues arise with any medical product that is used in combination with
Page 47 - Even if we are able to commercialize our drugs and any approved drug candidates, the drugs may becom
Page 48 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain regula
Page 49 - Our drugs and any future approved drug candidates may fail to achieve the degree of market acceptanc
Page 50 - We have limited experience in marketing third-party drugs and no experience in launching an internal
Page 51 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 52 - We may explore the licensing of commercialization rights or other forms of collaboration worldwide,
Page 53 - The illegal distribution and sale by third parties of counterfeit versions of our drugs or stolen pr
Page 54 - We have incurred significant net losses since our inception and anticipate that we will continue to
Page 55 - Raising additional capital may cause dilution to our shareholders, restrict our operations or requir
Page 56 - Risks Related to Our Intellectual Property
Page 57 - inter partes
Page 58 - We may not be able to protect our intellectual property rights throughout the world.
Page 59 - ex parte inter partes
Page 60 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 61 - If we do not obtain patent term extension and data exclusivity for any drug candidates we may develo
Page 62 - We may not be successful in obtaining or maintaining necessary rights for our development pipeline t
Page 63 - We expect to rely on third parties to manufacture at least a portion of our clinical and commercial
Page 64 - N/A
Page 65 - If third-party manufacturers fail to comply with manufacturing regulations, our financial results an
Page 66 - N/A
Page 67 - Risks Related to Our Industry, Business and Operations
Page 68 - We have significantly increased the size and capabilities of our organization, and we may experience
Page 69 - If we engage in acquisitions or strategic partnerships, this may increase our capital requirements,
Page 70 - If we fail to comply with the U.S. Foreign Corrupt Practices Act or other anti-bribery laws, our rep
Page 71 - Our internal computer systems, or those used by our CROs or other contractors or consultants, may fa
Page 72 - Business disruptions could seriously harm our future revenue and financial condition and increase ou
Page 73 - We are subject to the risks of doing business globally.
Page 74 - Risks Related to Our Doing Business in the PRC
Page 75 - There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulati
Page 76 - We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any
Page 77 - We may be treated as a resident enterprise for PRC tax purposes under the EIT Law and we may therefo
Page 78 - Restrictions on currency exchange may limit our ability to utilize our revenue effectively.
Page 79 - Our business benefits from certain financial incentives and discretionary policies granted by local
Page 80 - Risks Related to the American Depositary Shares
Page 81 - We may be subject to securities litigation, which is expensive and could divert management attention
Page 82 - We are a Cayman Islands company. Because judicial precedent regarding the rights of shareholders is
Page 83 - Anti-takeover provisions in our charter documents may discourage our acquisition by a third party, w
Page 84 - Our amended and restated memorandum and articles of association provide that any shareholder bringin
Page 85 - You may not receive distributions on our ordinary shares or any value for them if it is illegal or i
Page 86 - If you are a Ten Percent Shareholder, you may be subject to adverse U.S. federal income tax conseque
Page 87 - Item 6. Exhibits.
Page 88 - EXHIBIT INDEX
Page 89 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer